{
    "clinical_study": {
        "@rank": "131232", 
        "brief_summary": {
            "textblock": "Identification of risks of the GlucoTab system in routine use."
        }, 
        "brief_title": "Risk Identification of the GlucoTab System in Routine Use", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": "Diabetes Mellitus"
        }, 
        "detailed_description": {
            "textblock": "A study to identify risks in routine use of the GlucoTab system for glycaemic management in\n      non-critically ill patients with type 2 diabetes at general wards."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  informed consent obtained after being advised of the nature of the study\n\n          -  type 2 diabetes or new-onset hyperglycaemia which require s.c. insulin therapy during\n             hospital stay\n\n          -  diabetes therapy supported by GlucoTab system\n\n        Exclusion Criteria:\n\n          -  type 1 diabetes mellitus\n\n          -  intravenous insulin therapy\n\n          -  hyperglycaemic episodes (ketoacidosis, hyperosmolar state) if they require\n             intravenous insulin therapy\n\n          -  gestational diabetes or pregnancy\n\n          -  known or suspected allergy to certain insulin types, named in the user manual\n\n          -  total parenteral nutrition (TPN)\n\n          -  any mental condition rendering the patient incapable of giving his consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "non-critically ill patients with type 2 diabetes at general wards"
            }
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02053077", 
            "org_study_id": "ClinDiab-05"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 31, 2014", 
        "location": {
            "contact": {
                "email": "katharina.neubauer@medunigraz.at", 
                "last_name": "Katharina M. Neubauer, MSc BSc", 
                "phone": "+4331638572841"
            }, 
            "facility": {
                "address": {
                    "city": "Graz", 
                    "country": "Austria", 
                    "state": "Styria", 
                    "zip": "8010"
                }, 
                "name": "Medical University of Graz"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Study to Identify Risks in Routine Use of the GlucoTab System for Glycaemic Management in Non-critically Ill Patients With Type 2 Diabetes at General Wards", 
        "overall_contact": {
            "email": "katharina.neubauer@medunigraz.at", 
            "last_name": "Katharina M. Neubauer, MSc BSc", 
            "phone": "+4331638572841"
        }, 
        "overall_official": {
            "affiliation": "Medical University of Graz", 
            "last_name": "Thomas R. Pieber, Univ.Prof.Dr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Austria: Ethikkommission", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Identification of risks of the GlucoTab system in routine use assessed by the percentage of blood glucose values <70 mg/dl and \u2265300 mg/dl", 
            "safety_issue": "Yes", 
            "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 1 week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02053077"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Medical University of Graz", 
            "investigator_full_name": "Pieber Thomas, MD", 
            "investigator_title": "Univ. Prof. Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "medication / device interaction (e.g. corticosteroids, parenteral bolus nutrition) number of hypoglycaemic events day time of hypoglycaemic events risk factors for hypoglycaemic events", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 1 week"
            }, 
            {
                "description": "number of re-initialisations of the GlucoTab decision support reasons of re-initialisations of GlucoTab decision support percentage GlucoTab treatment covers patient stay percentage of GlucoTab use per eligible patient with type 2 diabetes or new-onset hyperglycaemia per ward", 
                "measure": "Usability", 
                "safety_issue": "No", 
                "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 1 week"
            }, 
            {
                "description": "mean daily blood glucose patient-day weighted mean blood glucose mean pre-breakfast blood glucose, mean pre-lunch blood glucose, mean pre-dinner blood glucose, mean bedtime blood glucose", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 1 week"
            }
        ], 
        "source": "Medical University of Graz", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medical University of Graz", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "December 2013"
    }
}